Carnosine
Also known as: Beta-Alanyl-L-Histidine, L-Carnosine, Ignotine
Overview
Carnosine is an endogenous dipeptide (β-alanyl-L-histidine) found in high concentrations in skeletal muscle, cardiac muscle, and neuronal tissue. It is a multifunctional bioactive molecule with antioxidant, metal-chelating, anti-glycation, and pH-buffering properties. Muscle carnosine levels decline with age and are elevated by beta-alanine supplementation. In the context of aging, carnosine has attracted attention for its ability to prevent protein glycation, chelate redox-active metals (Cu²⁺, Zn²⁺), and extend cellular lifespan in culture studies. It has also been studied for cognitive protection and exercise performance.
Mechanism of Action
Carnosine acts through multiple complementary mechanisms: (1) Antioxidant — directly quenches reactive oxygen species and singlet oxygen; (2) Anti-glycation — reacts with reducing sugars and aldehyde carbonyl groups, preventing AGE (advanced glycation end-product) formation on long-lived proteins; (3) Metal chelation — forms stable complexes with Cu²⁺ and Zn²⁺, reducing metal-catalyzed oxidative damage; (4) pH buffering — histidine's imidazole group (pKa ~6.8) buffers intramuscular pH during high-intensity exercise, delaying fatigue; (5) Transglycation — can remove glycation adducts from already-glycated proteins.
Potential Benefits
- Anti-glycation protection of long-lived proteins
- Intramuscular pH buffering during high-intensity exercise
- Neuroprotection in models of Alzheimer's disease
- Antioxidant activity in ischemia/reperfusion models
- Potential lifespan extension (animal models)
- Metal chelation reducing oxidative damage
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 500 mg daily with breakfast |
| Intermediate | 1000 mg daily split AM/PM |
| Advanced | 1500-2000 mg daily split 2x (often with zinc) |
| Cycle Duration | Continuous supplementation |
Dipeptide (β-alanyl-L-histidine). Rapidly hydrolyzed by serum carnosinase — β-alanine is the practical precursor for muscle carnosine loading.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (capsule/powder) Low (serum carnosinase hydrolysis) — but muscle uptake occurs via β-alanine
Standard supplement route. Consider β-alanine for performance ergogenic use.
Topical/ophthalmic (NAC + carnosine) Local
N-acetyl-carnosine eye drops marketed (controversially) for cataracts.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Carnosine:
Glycation Defense Stack
Anti-glycation and mitochondrial support — carnosine scavenges carbonyls, benfotiamine blocks AGE pathways, ALA supports redox balance.
Performance Stack
β-Alanine (carnosine precursor) 3.2-6.4 g daily + creatine 3-5 g daily for muscle buffering and phosphagen capacity.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store capsules/tablets at room temperature in a dry, dark place. Liquid formulations refrigerated. |
|---|
Oral peptide — no reconstitution required. Follow product label for storage specifics.
Need exact syringe measurements?
Amino Acid Sequence
β-Ala-His
Side Effects & Safety
- Generally well-tolerated
- Beta-alanine component: paresthesia (tingling) at high beta-alanine doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store at room temperature (15-25°C) in a dry, dark place. Keep tightly closed. Do not refrigerate capsules. |
Synergistic Compounds
The following compounds have been studied alongside Carnosine for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.